Grünenthal Acquires Valinor Pharma for Approximately $250M

Unilever Acquires Grüns for $1.2 Billion

April 14, 2026

Consumer Products

Unilever has signed an agreement to acquire Grüns, the US greens supplement brand, for $1.2 billion in a full acquisition valued at a significant premium to its prior private valuation. The deal is expected to close in H2 2026, pending regulatory approval, as Unilever looks to scale adherence-first gummy wellness products through its global FMCG distribution.

Grünenthal Acquires Kyowa Kirin’s 49% Stake in Grünenthal Meds JV

March 2, 2026

Pharmaceuticals

Grünenthal acquired Kyowa Kirin International’s 49% stake in Grünenthal Meds, taking full ownership of the joint venture created in 2023 to market Grünenthal’s established medicines portfolio. The JV manages a portfolio of 12 established brands across six therapeutic areas and more than 60 markets, with key products including Abstral, PecFent, Moventig, and Adcal-D3.

Merck to Acquire Verona Pharma for Approximately $10 Billion

July 9, 2025

Pharmaceuticals

Merck, through a subsidiary, entered into a definitive agreement to acquire Verona Pharma in a transaction valued at approximately $10 billion (at $107 per ADS). The acquisition is intended to add Ohtuvayre (ensifentrine) to Merck’s cardio-pulmonary pipeline, following FDA approval for COPD in June 2024.

Novartis AG Acquires Chinook Therapeutics

June 12, 2023

Biotechnology

Novartis AG agreed to acquire Chinook Therapeutics for $40 per share in cash, with contingent value rights of up to $4 per share tied to regulatory milestones —bringing total consideration to as much as approximately $3.5 billion. The acquisition, approved by both companies' boards, brings Chinook's kidney-disease pipeline into Novartis' renal portfolio and was expected to close in the second half of 2023 subject to customary conditions.

Graybar Acquires Valin Corporation

May 1, 2023

Industrial Services

Graybar has entered into an agreement to acquire Valin Corporation, a San Jose–based distributor of automation, filtration, fluid handling, heating and process control products and systems that operates 12 locations across the western and southwestern United States. Valin will continue to operate under its existing name and leadership team as a Graybar subsidiary; the transaction was expected to close May 1, 2023.

Partners Group Acquires Pharmathen from BC Partners

July 19, 2021

Pharmaceuticals

Partners Group has agreed to acquire Pharmathen, the leading European drug delivery technology and pharmaceutical manufacturing company, from BC Partners in a transaction valued at approximately EUR 1.6 billion. The deal transfers control of Pharmathen to Partners Group (acting on behalf of its clients) and is aimed at supporting the company’s continued growth — including an intensified push into the US market — building on strong R&D and manufacturing capabilities.